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Abstract
 
To elucidate the mechanism(s) by which Vav3, a new member of the Vav family proteins, par-
ticipates in B cell antigen receptor (BCR) signaling, we have generated a B cell line deficient in
Vav3. Here we report that Vav3 influences phosphoinositide 3-kinase (PI3K) function through
Rac1 in that phosphatidylinositol-3,4,5-trisphosphate (PIP
 
3
 
) generation was attenuated by loss
of Vav3 or by expression of a dominant negative form of Rac1. The functional interaction be-
tween PI3K and Rac1 was also demonstrated by increased PI3K activity in the presence of
GTP-bound Rac1. In addition, we show that defects of calcium mobilization and c-Jun NH
 
2
 
-
terminal kinase (JNK) activation in Vav3-deficient cells are relieved by deletion of a PIP
 
3
 
 hy-
drolyzing enzyme, SH2 domain-containing inositol polyphosphate 5
 
 
 
-phosphatase (SHIP).
Hence, our results suggest a role for Vav3 in regulating the B cell responses by promoting the
sustained production of PIP
 
3
 
 and thereby calcium flux.
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Introduction
 
Stimulation of the B cell antigen receptor (BCR)
 
*
 
 leads to
the sequential activation of protein tyrosine kinases (PTKs)
that phosphorylate numerous cellular proteins including
Vav isoforms and phospholipase C (PLC)-
 
 
 
2 (1–4). The
proto-oncogene Vav (herein referred to as Vav1) was first
discovered by virtue of a mutation that rendered it able to
transform fibroblasts. Vav1 contains a guanine nucleotide
exchange factor (GEF) domain for the Rho/Rac/Cdc42
family of small GTPases, a pleckstrin homology (PH) do-
main, and two src homology (SH)3 domains that flank one
SH2 domain (5). In vitro studies show that the GEF activ-
ity of Vav1 is regulated by tyrosine phosphorylation (6) and
by inositol lipids that interact with the Vav1 PH domain
(7). However, whether this mechanism operates in vivo is
still unclear.
Since Vav1 discovery, two new Vav members (Vav2 and
Vav3) have been identified. Although all Vav family pro-
teins have similar structural features, they display different
expression patterns. Vav1 is primarily expressed in hemato-
poietic lineages (8), while Vav2 and Vav3 have a relatively
broad expression profile (9–11).
Vav1 has been shown to be critical for T cell develop-
ment as well as mast cell activation (12–15). Moreover, the
importance of Vav1 and Vav2 proteins for B cell develop-
ment and activation has been recently underscored by gene
targeting and overexpression experiments. The B cell de-
velopmental and functional defects are relatively mild in
mice lacking either Vav1 or Vav2, while double-deficient
mice exhibit more severe defects (12, 13, 16, 17). The
small numbers of peripheral B cells which can develop in
the absence of both Vav1 and Vav2 display a profound de-
fect in BCR-mediated calcium mobilization. Conversely,
overexpression of either Vav1 or Vav2 in Bal-17 B cells re-
sults in an increase of BCR-mediated calcium mobiliza-
tion, thereby leading to enhancement of nuclear factor of
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3
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-phosphatase. 
190
 
A Role of Vav3 in BCR Signaling
 
activated T cell (NF-AT) activation (18). However, the
exact molecular mechanism(s) by which Vav1 and Vav2
participate in BCR signaling still remains to be determined.
Moreover, despite the high expression of Vav3 in periph-
eral lymphocytes and spleen cells (10, 11), the role of Vav3
in BCR signaling has not been addressed.
In this study, we first characterized BCR signaling of
DT40 B cells deficient in Vav3. Then we examined how
Vav3 exerts its functions. Vav3-deficient B cells exhibited
similar defects to those in phosphoinositide 3-kinase
(PI3K)-deficient B cells, which led us to consider the func-
tional interaction between Vav3 and PI3K. Here we show
that phosphatidylinositol-3,4,5-trisphosphate (PIP
 
3
 
) gener-
ation and subsequent Akt activation are attenuated by loss
of Vav3 or by introduction of dominant negative Rac1.
Supporting the positive effect of Vav3 on PI3K, PI3K en-
zymatic activity is upregulated by Rac1 in a GTP-depen-
dent manner. Furthermore, the defects in Vav3-deficient
cells can be suppressed by deletion of a PIP
 
3
 
 hydrolyzing
enzyme, SH2 domain-containing inositol polyphosphate
5
 
 
 
-phosphatase (SHIP). Thus, our data suggest that Vav3 is
involved in sustaining PIP
 
3
 
 generation, which in turn regu-
lates downstream events such as calcium flux.
 
Materials and Methods
 
Cells, Abs, and Reagents.
 
Various mutant chicken DT40 B
cells were cultured as described previously (19, 20). Human 293T
cells were cultured in DME containing 10% FCS. Preparation of
murine splenic B cells was described previously (21).
Anti-Vav3 and anti-Vav2 Abs were obtained by immunizing
rabbits with bacterially expressed GST fusion protein containing
chicken Vav3 (128–193 amino acid region) and chicken Vav2
(311–430 amino acid region), respectively. The anti-chicken IgM
mAb (M4), rabbit anti-Lyn Abs, and rabbit anti-PLC-
 
 
 
2 Abs
were described previously (22). The following Abs were pur-
chased: anti-phosphotyrosine mAb (4G10), anti-Rac1 mAb, and
rabbit anti-PI3K p85 Abs from Upstate Biotechnology, goat anti-
PI3K p110
 
 
 
 Abs (sc-1331) and goat anti-Akt1 Abs (sc-1618)
from Santa Cruz Biotechnology, Inc., anti-c-Jun NH
 
2
 
-terminal
kinase 1 (JNK1) mAb from BD PharMingen, anti-T7•Tag mAb
from Novagen, and goat anti-mouse IgM from Jackson Im-
munoResearch Laboratories. Recombinant GST-Rac1 proteins
were purchased from Cytoskeleton.
 
cDNA Cloning.
 
A chicken EST clone (GenBank/EMBL/
DDBJ accession no. AJ395373) was found by homology search of
the NCBI database using the mouse Vav3 cDNA sequences. A
 
 
 
ZAP DT40 cDNA library was screened by using the EST
cDNA fragment as a probe, giving rise to isolation of 26 clones.
The longest insert that contains the open reading frame encoding
846 amino acids has been deposited into GenBank (GenBank/
EMBL/DDBJ accession no. AY046915).
To isolate chicken Vav2 cDNA, a cDNA fragment encoding
human Vav2 was used as a probe for screening the 
 
 
 
ZAP DT40
cDNA library under the low-stringency conditions. 23 positive
clones were identified and further characterized. The complete
sequence of the longest insert (encoding protein of 839 amino ac-
ids) has been deposited into GenBank (GenBank/EMBL/DDBJ
accession no. AY046916).
 
Expression Constructs and Transfection.
 
The chicken Vav3 GEF
mutant construct (altering amino acids 336–342 from LLLQELV
to IIIQDAA) (23) was generated by oligonucleotide-directed
mutagenesis. The cDNAs encoding wild-type Vav3, its GEF
mutant, or wild-type Vav2 were subcloned into the pApuro ex-
pression vector (24). T7-tagged Btk cDNA in the pApuro ex-
pression vector was described previously (25). These constructs
were transfected into Vav3-deficient DT40 cells by electropora-
tion, and selected in the presence of puromycin (0.5 
 
 
 
g/ml). Ex-
pression of transfected cDNAs was confirmed by Western blot
analysis.
cDNAs encoding bovine p85
 
 
 
 subunit and chicken p110
 
 
 
subunit of PI3K were provided by Drs. Michael D. Waterfield
(London, UK) and Peter K. Vogt (La Jolla, CA), respectively. A
kinase-negative p110
 
 
 
 cDNA (R916P) was generated by oligo-
nucleotide-directed mutagenesis. These cDNAs were subcloned
into the pAzeo expression vector (26). 293T cells were transfected
with p85
 
 
 
 cDNA together with either wild-type or kinase-nega-
tive p110
 
 
 
 cDNA using calcium phosphate precipitation method.
 
Generation of Vav3- and PI3K p110
 
 
 
-deficient DT40 Cells.
 
DT40 genomic fragments of Vav3 and PI3K p110
 
 
 
 were ob-
tained by PCR. The targeting vectors pVav3-bsr, pVav3-hisD,
and pVav3-neo were constructed by replacing the 0.3-kb ge-
nomic DNA containing exons that encode a part of Dbl homol-
ogy region (308–338 amino acids) with bsr, hisD, and neo cas-
settes, respectively. These cassettes were flanked by 2.5 kb and
6.5 kb of Vav3 genomic sequences on the 5
 
 
 
 and 3
 
 
 
 sides, respec-
tively. To isolate Vav3-deficient cells, DT40 cells transfected se-
quentially with pVav3-hisD and pVav3-bsr were selected in the
presence of proper drugs. DT40 cells deficient for both SHIP and
Vav3 were generated by successive transfection with pVav3-hisD
and pVav3-neo into SHIP-deficient cells (19).
The neo and hisD targeting vectors of p110
 
 
 
 were constructed
by replacing the 0.5-kb genomic fragment containing exons cor-
responding to a part of kinase domain (831–888 amino acids)
with neo and hisD cassettes, respectively. These constructs
spanned 1.7 kb (5
 
 
 
 side) and 0.8 kb (3
 
 
 
 side) of p110
 
 
 
 sequences.
These targeting vectors were sequentially transfected into DT40
cells to obtain a null mutant.
Selection for drug-resistance clones was performed by using
either alone or combinations of histidiol (1 mg/ml), blastcidin S
(50 
 
 
 
g/ml), and G418 (2 mg/ml).
 
Biochemical Analyses.
 
For immunoprecipitation, cells were
solubilized in lysis buffer (10 mM Tris-HCl [pH7.5], 150 mM
NaCl, and 1% Nonidet P-40) supplemented with protease and
phosphatase inhibitors as described previously (24). Precleared ly-
sates were incubated with proper Abs and protein A-agarose. For
Western blot analysis, immunoprecipitates, affinity precipitates,
or whole-cell lysates were resolved on SDS-PAGE, transferred to
polyvinylidene difluoride (PVDF) membrane (Bio-Rad Labora-
tories), and detected by the indicated Abs and enhanced chemilu-
minescence (ECL) system (Amersham Pharmacia Biotech). In
vitro kinase assays of Akt and JNK1 were performed as described
previously (27). The reaction products were resolved on SDS-
PAGE, dried, and subjected to quantification of radioactivity by
using a Fuji FLA2000 bioimaging analyzer (Fuji Photo Film).
Based on these analyses, the stimulation folds are shown in Figs. 3
E, 4 B, 5 C, 5 D, 9 B, 9 C, and 10 C. Phospholipase hydrolysis
activity of PLC-
 
 
 
2 was measured by quantitating inositol 1,4,5-
trisphosphate (IP
 
3
 
) production as described previously (28).
For affinity precipitation assays using GST-CRIB (Cdc42/Rac
interactive binding domain [CRIB] of rat PAK1 [amino acid 1–125]
fused to GST), bacterially expressed GST-CRIB, prebound
glutathione-sepharose beads (20 
 
 
 
l packed beads, 40 
 
 
 
g of pro-
tein) were prepared as described (29). Cell lysates in lysis buffer 
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(25 mM Hepes [pH 7.3], 150 mM NaCl, 5 mM EGTA, 20 mM
 
 
 
-glycerophosphate, 10 mM NaF, 2 mM sodium vanadate, 0.5%
Triton X-100, 4% glycerol, 5 mM dithiothreitol, 0.5 mM PMSF,
and 5 
 
 
 
g/ml each leupeptin and pepstatin) were incubated with
the beads for 10 min at 4
 
 
 
C. After quick wash in the lysis buffer,
bound proteins were eluted from the beads with SDS-PAGE
sample buffer. Eluted samples were resolved on 12.5% SDS-
PAGE and subsequently subjected to Western blot analysis using
anti-Rac1 mAb.
Glycolipid-enriched microdomains (GEMs) were isolated from
cell lysates in Triton X-100 and floatation on sucrose density gra-
dients as described previously (30).
The amount of proteins detected by Western blotting was de-
termined by scanning the autoradiography followed by process-
ing of the data with NIH-image program. Based on these analy-
ses, the stimulation folds are shown in Figs. 3 C, 4 D, 5 B, and
10 B.
 
Measurements of [Ca
 
2
 
 
 
]
 
i
 
, Inositol Phosphates, and Phosphoinosi-
tides.
 
Calcium mobilization was measured using fura-2 in a bulk
spectrofluorimeter as described (30). Production of IP
 
3 
 
was mea-
sured using a commercial IP
 
3
 
 assay system (Biotrak TRK 1000;
Amersham Pharmacia Biotech) as described previously (26).
Determination of phosphatidylinositol-4,5,-bisphosphate (PIP
 
2
 
)
was also performed by using the Biotrak TRK 1000 assay kit ac-
cording to the manufacturer’s instructions. Briefly, PIP
 
2
 
 extracted
from the cells using methanol/chloroform/12 M HCl (80:40:1
vol/vol) were hydrolyzed into IP
 
3
 
 by 1 M KOH at 100
 
 
 
C for 15
min. Samples were neutralized and then assayed as described
above.
Thin-layer chromatography (TLC) analyses of phosphoinosi-
tides were performed by 
 
32
 
P labeling of cells, extraction of lipids,
and TLC analysis as described previously (27, 31). The radioac-
tivity of PIP
 
3 
 
spots was quantified by using a Fuji FLA2000 bio-
imaging analyzer and was normalized to the radioactivity in phos-
pholipids of the samples. Then, the resulting values were
normalized to the value at time zero of BCR stimulation for each
of three independent experiments and averaged.
 
PI3K Assay.
 
PI3K activity was essentially measured as de-
scribed previously with minor modifications (32). 293T cells
transfected together with PI3K p85
 
 
 
 and p110
 
 
 
 cDNAs were
solubilized in lysis buffer (20 mM Tris-HCl [pH8.0], 100 mM
NaCl, 1 mM EDTA, 0.3 mM dithiothreitol, 0.5 mM PMSF, 1%
Triton X-100, and 10 
 
 
 
g/ml each aprotinin and leupeptin), and
PI3K was immunoprecipitated with anti-p85 Abs. Immunocom-
plexes were collected on protein A-agarose beads, washed twice
with wash buffer (20 mM Tris-HCl [pH8.0], 100 mM NaCl,
and 10 mM MgCl
 
2
 
), and washed once with kinase assay buffer
(10 mM Tris-HCl [pH7.4] and 10 mM MgCl
 
2
 
). Wild-type or
mutant GST-Rac1 recombinant proteins (2 
 
 
 
g) prebound to
different guanine nucleotides were added to the washed immu-
noprecipitates, and PI3K activity was assayed by the addition of
5 
 
 
 
g of sonicated phosphatidylinositol and phosphatidylserine
(1:1) and 20 
 
 
 
M [
 
 
 
-
 
32
 
P]ATP (200 
 
 
 
Ci/ml) in 45 
 
 
 
l of kinase
assay buffer. The reactions were terminated after 10 min at 25
 
 
 
C
by the addition of 100 
 
 
 
l of 1 M HCl. The lipids were then im-
mediately extracted with 200 
 
 
 
l of chloroform/methanol (1:1
vol/vol), and the organic phase was washed once with 80 
 
 
 
l of
methanol/1 M HCl (1:1 vol/vol). Extracted products were sub-
mitted to TLC on potassium oxalate-coated silica gel 60 plates
(Merck) in a chloroform/methanol/4 M ammonium hydroxy-
side (9:7:2 vol/vol) developing solvent. Phosphorylated products
were visualized and quantified by a Fuji FLA2000 bioimaging
analyzer.
To determine BCR-induced PI3K activity, DT40 cells were
solubilized in lysis buffer (20 mM Tris-HCl [pH8.0], 137 mM
NaCl, 1% Triton X-100, 10% glycerol, 2 mM EDTA, 1 mM so-
dium vanadate, 1 mM PMSF, 1 
 
 
 
g/ml leupeptin, and 0.1 
 
 
 
g/ml
aprotin) (33), and solubilized proteins were immunoprecipitated
by using anti-p85 Abs and protein A-agarose beads. Beads were
washed twice with lysis buffer and washed three times with wash
buffer. After wash in the kinase assay buffer, immune complexes
were then subjected to PI3K assay as described above.
 
Results
 
Vav3 Is Tyrosine Phosphorylated by BCR Cross-linking.
 
Vav3-specific antibodies were used to establish whether
Vav3 is tyrosine phosphorylated after BCR engagement.
Increased Vav3 phosphorylation in isolated murine B cells,
as measured with anti-phosphotyrosine mAb 4G10, was
apparent after 1 min of BCR stimulation, with a peak level
detected 3 min after BCR cross-linking, after which phos-
phorylation declined (Fig. 1). These data demonstrate that
Vav3, like Vav1 and Vav2 (18), is a substrate for PTKs
downstream of the BCR in murine primary B cells.
Chicken DT40 B cells are a useful model for studies of
BCR-mediated signal transduction; therefore, we exam-
ined whether chicken Vav3 also underwent tyrosine phos-
phorylation in DT40 B cells. As shown in Fig. 1, BCR
stimulation of DT40 B cells resulted in a rapid increase in
Vav3 phosphorylation, although the kinetics differed from
those of murine primary B cells. Vav3 tyrosine phosphory-
lation was already maximal at 1 min, after which phos-
phorylation gradually declined to a lower level.
 
Role of Vav3 in BCR Signaling.
 
To elucidate the func-
tion of Vav3, we established Vav3-deficient DT40 lines by
the gene-targeting method (see Materials and Methods).
Lack of Vav3 expression was verified by Western blot analy-
sis (Fig. 2 A). The level of cell surface expression of BCR on
Vav3-deficient DT40 cells was essentially the same as that on
parental DT40 cells (Fig. 2 B). Little change of the BCR-
induced overall tyrosine phosphorylation was detected be-
tween wild-type and Vav3-deficient DT40 cells (data not
shown), suggesting that the BCR-associated PTKs such as
Lyn and Syk are activated normally in the absence of Vav3.
Figure 1. Vav3 is tyrosine phosphorylated after antigen-receptor liga-
tion in B lymphocytes. Primary B cells purified from mouse spleen (107
cells per sample, left panels) and chicken DT40 B cells (5   106 cells per
sample, right panels) were incubated with 15  g/ml polyclonal F(ab )2
anti–mouse IgM and 4  g/ml monoclonal anti–chicken IgM, M4, respec-
tively. After stimulation, immunoprecipitates with anti-Vav3 Abs were
separated on 7.5% SDS-PAGE and analyzed by Western blotting with
4G10 mAb (top) and anti-Vav3 Abs (bottom). IP, immunoprecipitation. 
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One of the hallmarks of BCR-mediated signaling is the
mobilization of intracellular calcium ([Ca
 
2
 
 
 
]
 
i
 
). Indeed, cal-
cium flux has been implicated in B cell maturation and im-
mune responses (21, 34). Therefore, we measured BCR-
induced calcium mobilization in wild-type and Vav3-deficient
B cells. As shown in Fig. 3 A, the peak height of the [Ca
 
2
 
 
 
]
 
i
 
increase upon receptor stimulation was decreased by 
 
 
 
50%
by loss of Vav3. This decrease in Vav3-deficient cells, com-
pared with wild-type cells, was still observed when extracel-
lular Ca
 
2
 
 
 
 was chelated with EGTA, suggesting the impair-
ment of calcium release from intracellular stores. In addition,
these mutant cells exhibited reduced BCR-mediated IP
 
3
 
generation (Fig. 3 B). Together, we conclude that the cal-
cium defect in Vav3-deficient DT40 B cells is, at least partly,
due to insufficient PLC-
 
 
 
2 activation. Normal calcium mo-
bilization as well as IP
 
3
 
 generation was restored by transfec-
tion of wild-type Vav3 cDNA (data not shown).
Figure 2. Generation of Vav3- and PI3K p110 -deficient DT40 B
cells. (A) Cell lysates were separated on 7.5% SDS-PAGE and analyzed by
Western blotting with anti-Vav3 Abs (left) or anti-p110  Abs (right). (B)
Cell surface expression of BCR on wild-type and mutant DT40 cells used
in this study: wt, parental DT40 cells; Vav3 , Vav3-deficient cells;
p110  , p110 -deficient cells; wt/Vav3 , Vav3-deficient cells expressing
wild-type Vav3; mGEF/Vav3 , Vav3-deficient cells expressing GEF mu-
tant Vav3; Vav2/Vav3 , Vav3-deficient cells overexpressing Vav2;
SHIP , SHIP-deficient cells; Vav3 /SHIP , Vav3/SHIP double-defi-
cient cells; Rac1DN, cells expressing dominant negative Rac1
(Rac1N17); Btk-T7, cells expressing Btk-T7; Btk-T7/Vav3 , Vav3-defi-
cient cells expressing Btk-T7. Unstained cells were used as negative con-
trols (dotted line).
Figure 3. Characterization of Vav3- and PI3K p110 -deficient DT40 B
cells. Cells were stimulated with M4 (4  g/ml) for indicated time periods
and then subjected to the following analyses. (A) Calcium mobilization.
Intracellular free calcium levels in Fura-2-loaded cells were monitored by a
fluorescence spectrophotometer. Calcium release from intracellular cal-
cium stores was measured in the presence of 1 mM EGTA (dotted line).
wt, wild-type. (B) IP3 generation. Soluble IP3 was extracted from 2   106
cells and subjected to a Biotrak competitive binding assay system. The re-
sults (2   106 cell equivalents per point) were shown by mean   standard
error of three independent experiments. (C) Tyrosine phosphorylation of
PLC- 2. Immunoprecipitation (IP) was performed with anti-PLC- 2
Abs. The blots (5   106 cell equivalents per lane) were stained with 4G10
mAb (top). The blots were stripped and reprobed with anti-PLC- 2 Abs
(bottom). (D) BCR-induced PLC- 2 activation. PLC- 2 was immuno-
precipitated from lysates (2   107 cell equivalents per point), and in vitro
phospholipase activity was measured as described in Materials and Meth-
ods. The results were shown by mean   standard error of three indepen-
dent experiments. (E) BCR-induced JNK1 activation. Lysates from 5  
106 cells were immunoprecipitated with anti-JNK1 mAb, and the resulting
immunoprecipitates were divided. Half of them was used for Western blot
analysis using anti-JNK1 mAb (bottom). The remaining half was used for
in vitro kinase assay using GST-c-Jun as an exogenous substrate. The ki-
nase reaction products were resolved on 12.5% SDS-PAGE, and their
phosphorylation was quantified by autoradiography (top).193 Inabe et al.
Previous studies including ours showed that B cells,
when treated with PI3K inhibitors such as wortmannin,
manifested the partial defects in calcium mobilization and
IP3 generation (31, 35–37). To formally demonstrate the
resemblance of the defects between Vav3- and PI3K-defi-
cient B cells, we took a genetic approach, as the PI3K in-
hibitors are known to inhibit other lipid metabolizing en-
zymes, in addition to PI3K (38). Heterodimer-type (class
Ia) PI3Ks consist of a regulatory subunit (p85) and a
catalytic subunit (p110) encoded by three distinct genes
(p110 , p110 , and p110 ; reference 39). Among three
p110 isoforms, p110  was dominantly expressed in DT40
B cells, as determined by Northern blot analysis (data not
shown). Thus, we established p110 -deficient DT40 B
cells (Fig. 2, A and B) and characterized them. In fact, both
calcium mobilization and IP3 generation were partially in-
hibited in p110 -deficient cells (Fig. 3, A and B). More-
over, in contrast to wild-type cells, p110 - and Vav3-defi-
cient B cells exhibited a reduction in both PLC- 2 tyrosine
phosphorylation and its in vitro lipase activity upon recep-
tor cross-linking (Fig. 3, C and D). Further resemblance
was observed in BCR-mediated JNK1 response; in vitro
kinase assay revealed attenuated JNK1 activation in both
p110 - and Vav3-deficient cells (Fig. 3 E).
Vav3 Regulates PI3K Activation through Rac1. The above
results suggest that Vav3 and PI3K p110  influence each
other’s functions or that these two molecules function in-
dependently, thereby contributing to downstream re-
sponses. To test these possibilities, we first determined
whether Vav3 modulated PI3K activation in BCR signal-
ing. As demonstrated in Fig. 4 A, BCR-mediated PIP3
generation was attenuated by  25% in Vav3-deficient
cells, while this attenuation was  30% in p110 -deficient
cells. As expected, inhibition extents of Akt activation in
Vav3- and p110 -deficient B cells correlated well with
those of PIP3 generation (Fig. 4 B). A previous study pro-
posed the possibility that Vav1 is involved in PIP2 synthesis
by stimulating PIP 5-kinase (40). As PIP2 is a substrate for
PI3K, attenuation of PIP3 generation in Vav3-deficient
cells might be similarly accounted for by insufficient re-
plenishment of PIP2 rather than by insufficient PIP3 syn-
thesis. However, this possibility is unlikely in DT40 B cells,
because we could not detect significant differences of PIP2
levels between wild-type and Vav3-deficient cells during
the course of BCR stimulation (Fig. 4 C). Therefore, we
conclude that Vav3 regulates PI3K activation in DT40 B
cells. PIP3 is thought to be involved in PLC- 2 activation
through its binding to the Btk PH domain and its subse-
quent activation (31, 37). Hence, our conclusion is further
supported by the observation that BCR-mediated tyrosine
phosphorylation of Btk was significantly reduced in Vav3-
deficient cells (Fig. 4 D).
As predicted, BCR-mediated Rac1 activation, as mea-
sured by a PAK-binding assay, was attenuated by  50% in
Vav3-deficient DT40 cells (Fig. 5 B). Introduction of wild-
type Vav3, but not its GEF mutant, into Vav3-deficient
cells restored Rac1 activation. Moreover, BCR-mediated
Akt activation was restored only by wild-type Vav3 (Fig. 5
Figure 4. Impairment of BCR-induced PI3K signaling in the absence
of Vav3. (A) PIP3 generation. Cells loaded with [32P]orthophosphate (107
cells per condition) were stimulated with M4 (4  g/ml) for indicated
time periods. PIP 3 was extracted and analyzed as described in Materials
and Methods. Fold increases of PIP3 level normalized to total phospholip-
ids after M4 stimulation were shown. These results were shown by mean  
standard error of three independent experiments. wt, wild-type. (B)
BCR-induced Akt activation. Lysates from 5   106 cells were immuno-
precipitated with anti-Akt1 Abs, and the resulting immunoprecipitates
were divided. Half of them was used for Western blot analysis using anti-
Akt1 Abs (bottom). The remaining half was used for in vitro kinase assay
using histone H2B as an exogenous substrate. The kinase reaction prod-
ucts were resolved on 15% SDS-PAGE, and their phosphorylation was
quantified by autoradiography (top). IP, immunoprecipitation. (C) PIP2
levels. Wild-type and Vav3-deficient DT40 cells (2   106) were stimu-
lated with M4 (4  g/ml) for indicated times and then processed to deter-
mine the levels of PIP2 as described in Materials and Methods. The results
(2   106 cell equivalents per point) were shown by mean   standard error
of three independent experiments. (D) Tyrosine phosphorylation of Btk.
Lysates from wild-type and Vav3-deficient DT40 cells expressing Btk-T7
were immunoprecipitated with anti-T7 mA. The blots (5   106 cell
equivalents per lane) were stained with 4G10 (top). The blots were
stripped and reprobed with anti-T7 mAb (bottom).194 A Role of Vav3 in BCR Signaling
C). Then, to formally demonstrate that the effect of Vav3
on PI3K is indeed mediated by Rac1, we examined DT40
cells expressing a dominant-negative form of Rac1, Rac1N17
(Fig. 5 A; reference 20). The transfected cells exhibited at-
tenuation of both PIP3 generation (Fig. 4 A) and Akt acti-
vation upon BCR engagement (Fig. 5 D).
Rac1 Stimulates PI3K Activity in a GTP-dependent Man-
ner. Optimal PI3K activation is thought to require at least
two events in the context of antigen receptor signaling; (a)
recruitment of PI3K to the plasma membrane, particularly
to GEMs (41–43); (b) an increase in the PI3K enzymatic
activity by its conformational change (44). To obtain more
insight into how Vav3 affects PI3K activation in BCR sig-
naling, we studied whether these two events were modu-
lated by Vav3-dependent Rac1 activation. First, we com-
pared BCR-mediated recruitment of PI3K p85 subunit to
GEMs in wild-type and Vav3-deficient cells, revealing no
differences (Fig. 6).
In vitro kinase experiments were employed to examine
the second possibility. Anti-p85 immunoprecipitates from
293T cells transfected with both PI3K p85  and p110 
subunits were mixed with different guanidine nucleotide-
bound forms of GST-Rac1 and subjected to a PI3K enzy-
matic assay. Consistent with a previous report (45), the
GTP-bound GST-Rac1 stimulated PI3K activity about
threefold, while GDP-bound GST-Rac1 stimulated the
PI3K activity by 1.2-fold (Fig. 7 A). As a negative control,
immunoprecipitates from 293T cells expressing wild-type
p85  and kinase-negative p110  were used, showing un-
detectable levels of in vitro PI3K activity in our assay con-
ditions. Proper expression and association of these two sub-
units were verified by Western blot analysis (Fig. 7 B). The
biological relevance of the above findings with 293T cells
was examined by precipitating PI3K from resting and stim-
ulated DT40 B cells and measuring its in vitro kinase activ-
ity. As shown in Fig. 7 C, Vav3-deficient B cells exhibited
reduced PI3K activation, and this defect was restored by
wild-type Vav3, but not its GEF mutant. Taken together,
these findings suggest that Rac1, after being activated by
Vav3, contributes to enzymatic activation of PI3K rather
than to its recruitment to GEMs.
BCR-mediated Tyrosine Phosphorylation of Vav3 Occurs
Normally in the Absence of PI3K p110 . Previous in vitro
studies place Vav1 downstream of PI3K; PIP3 binds to the
Vav1 PH domain and promotes tyrosine phosphorylation-
mediated activation of the enzymatic activity of Vav1 (7).
To determine whether PI3K similarly modulates Vav3 acti-
vation, we assessed Vav3 tyrosine phosphorylation and sub-
sequent Rac1 activation using p110 -deficient DT40 B
cells. As shown in Fig. 8, significant changes in both pa-
rameters in wild-type versus mutant DT40 cells could not
be detected, except a small decrease of Vav3 tyrosine phos-
phorylation after 10 min stimulation in p110 -deficient
cells. These readouts could not be affected in DT40 B cells,
even when treated with 100 nM wortmannin.
Figure 5. Vav3 regulates BCR-mediated Akt response through Rac1.
(A) Expression levels of wild-type (wt) or GEF mutant Vav3 in Vav3-
deficient DT40 cells (left) or of Myc-tagged dominant-negative Rac1 in
wild-type DT40 cells (right). Whole-cell lysates were analyzed by West-
ern blotting using anti-Vav3 Abs (left) or anti-Rac1 mAb (right). (B)
Rac1 activation in response to BCR cross-linking. Cells (5   106) were
stimulated with M4 (4  g/ml), and cell lysates were mixed with beads
containing the CRIB of PAK. Elutes of the beads (top) or cell lysates
(bottom) were resolved on 12.5% SDS-PAGE and subjected to Western
blot analysis with anti-Rac1 mAb. AP, affinity precipitation. (C and D)
Effects of mutations of Vav3 and Rac1 on Akt responses. Cells were stim-
ulated with M4 (4  g/ml) for indicated times. Cell lysates were subse-
quently subjected to in vitro kinase assay of Akt, as described in the
legend to Fig. 4 B. IP, immunoprecipitation.
Figure 6. Inactivation of Vav3 does not affect PI3K recruitment to gly-
colipid-enriched microdomains (GEMs). Wild-type (wt) and Vav3-defi-
cient DT40 cells (108 cells per condition), unstimulated (minus symbol)
or stimulated with M4 (4  g/ml) for 1 min (plus symbol), were lysed and
then subjected to discontinuous sucrose density gradient centrifugation.
Fractions (30  l/lane, numbered from low to high density) were resolved
on 7.5% SDS-PAGE and immunoblotted with anti-p85 Abs or anti-Lyn
Abs. Lyn was used as a positive control for GEM fraction.195 Inabe et al.
Deletion of SHIP Suppresses Defects in Vav3-deficient Cells.
Collectively, the above data suggest that Vav3 functions
upstream of PI3K activation, thereby contributing to cal-
cium mobilization and JNK1 activation. This hypothesis
predicts that defects in Vav3-deficient DT40 cells should
be suppressible by manipulations which enhance PIP3 ac-
cumulation. To test this prediction, we deleted a PIP3 hy-
drolyzing enzyme, SHIP, in a Vav3-deficient background.
As shown in Fig. 9, both of these defects, in addition to
downmodulation of Akt in Vav3-deficient cells, were re-
lieved by deletion of SHIP. Hence, reduction in PIP3 levels
likely results in inhibition of calcium mobilization as well as
JNK1 activation in Vav3-deficient cells.
Overexpression of Vav2 Rescues Defects in Vav3-deficient
Cells. Although we cloned chicken homologs of Vav2
and Vav3, Vav1 isoform could not be detected in spite of
our several efforts including low-stringency cross-hybrid-
ization, degenerative-oligonucleotide reverse transcription
(RT)-PCR, and EST database search. Given the evidence
that Vav2, like Vav3, undergoes tyrosine phosphorylation
after BCR cross-linking in DT40 B cells (data not shown),
Vav2 could have overlapping functions with those of Vav3.
If so, we speculate that Vav2, once overexpressed in a
Vav3-deficient background, can compensate some func-
tional defects of Vav3-deficient DT40 B cells. To examine
this possibility, we established Vav3-deficient cells that ex-
pressed fourfold higher level of Vav2 than that in wild-type
cells. As shown in Fig. 10, defects in Rac1, Akt, and cal-
cium responses were compensated by overexpression of
Vav2, suggesting the existence of some functional redun-
dancy between Vav2 and Vav3.
Discussion
Vav1 and Vav2 play an important role in coupling BCR
to calcium flux (16, 17). Here we extended this concept to
show that Vav3, like Vav1 and Vav2, participates in cal-
cium mobilization. Then, we addressed the mechanisms by
which Vav3 influences the calcium flux. Many aspects of
PLC- 2/calcium defects are similar in Vav3-deficient and
PI3K p110 -deficient DT40 B cells. For instance, BCR-
mediated PLC- 2 tyrosine phosphorylation and subse-
Figure 7. PI3K enzymatic activity is upregulated by Rac1 in a GTP-
dependent manner. (A and B) Effect of Rac1 on PI3K activity in vitro. (A)
p85 was immunoprecipitated from lysates of 293T cells transfected with
plasmids encoding either wild-type (wt; lane 1–4) or kinase-negative (KN;
lane 5–8) p110 , together with p85 . Immunoprecipitates were mixed
with GST/GTP S (lane 1 and 5), GST-Rac1/GDP S (lane 2 and 6),
GST-Rac1/GTP S (lane 3 and 7), or GST-Rac1N17/GTP S (lane 4 and
8), and PI3K activity was assayed as described in Materials and Methods. In
the top panel, one of representative results is shown. The bottom panel
shows quantitative analysis of PI3K activity. The intensity of the PIP spots
revealed in autoradiogram was measured by scanning densitometry. The
activity in the presence of GST/GTP S was used to normalize individual
activities in each experiment. The results were shown by mean   standard
error of three independent experiments. (B) Aliquots of immunoprecipi-
tates with anti-p85 Abs were subjected to Western blot analysis using anti-
p85 Abs (left) or anti-p110  Abs (right). (C) BCR-induced PI3K activity.
Lysates from 5   106 cells were immunoprecipitated with anti-p85 Abs,
and the immunoprecipitates were subjected to PI3K assay. One of the rep-
resentative results is shown in the top panel. Aliquots of immunoprecipi-
tates were used for Western blot analysis with anti-p85 Abs (bottom). The
doublet bands shown in the immunoblot are presumably due to p85  and
p85  isoforms, as we used anti-pan-p85 Abs. IP, immunoprecipitation.
Figure 8. Neither disruption of PI3K p110  nor treatment with wort-
mannin affects Vav3 activation. Treatment with 100 nM wortmannin was
conducted 20 min before stimulation. Wild-type (wt) and p110 -defi-
cient DT40 cells were stimulated with M4 (4  g/ml) and then subjected
to the following analyses. (A) Tyrosine phosphorylation of Vav3, as de-
scribed in the legend to Fig. 1. IP, immunoprecipitation. (B) Rac1 activa-
tion, as described in the legend to Fig. 5 B. AP, affinity precipitation.196 A Role of Vav3 in BCR Signaling
quent IP3 generation are similarly attenuated in both back-
grounds (Fig. 3, B and C), thereby promoting us to exam-
ine the relationship between Vav3 and PI3K. Previous in
vitro studies favor the model that PI3K functions upstream
of Vav as regulators of GEF activity (7). Our data instead
support a different mechanism, in which Vav3 functions as
a positive regulator of PI3K in BCR signaling.
We demonstrate that BCR-mediated PIP3 generation
and subsequent Akt activation are inhibited by loss of Vav3
(Fig. 4, A and B) or by introduction of Rac1N17 into
DT40 B cells (Figs. 4 A and 5 D). Strengthening the idea
that Vav3-mediated Rac1 activation is involved in PIP3
generation, a Vav3 GEF mutant fails to restore Rac1 acti-
vation as well as PI3K activation (Figs. 5 B and 7 C).
Hence, the results presented here are consistent with re-
ports that, in Jurkat T cells and RBL mast cells, Akt activa-
tion is blocked by overexpression of dominant negative
Rac1 and by treatment of Clostridium sordellii lethal toxin, a
Rac-inactivating toxin, respectively (46, 47). The inhibi-
tion of PIP3 generation in Vav3-deficient cells could be ac-
counted for by the decreased availability of a PI3K sub-
strate, PIP2, and/or by the decreased PIP3 synthesis from
PIP2. Two lines of our evidence suggest that the latter
mechanism is dominantly operating in DT40 B cells. First,
overall PIP2 levels are not significantly changed between
wild-type and Vav3-deficient DT40 B cells (Fig. 4 C). Sec-
ond, the enzymatic activity of PI3K, a responsible kinase
for PIP3 synthesis, is indeed increased by Rac1 in a GTP-
dependent manner (Fig. 7 A). However, the former mech-
anism cannot be completely excluded by our data. Recent
studies showed that PI3K activation occurs in subdomains
of the plasma membrane, called GEMs or lipid rafts (42),
suggesting that PIP2 localized specifically in GEMs serves as
a PI3K substrate in BCR signaling context. In this regard,
our overall PIP2 assay system might not have sufficed
enough to detect small changes in the level of PIP2 which
reside in GEMs.
Based on the in vitro data that PIP3 binds to the Vav1
PH domain and promotes PTK-mediated activation of its
GEF activity, PI3K has been proposed to function as an up-
stream regulator for Vav family members (7). Hence, our
finding that Vav3 is involved in PI3K activation implies
two possibilities; (a) in addition to regulation of PI3K by
Vav3, PI3K could reciprocally influence Vav3 function,
Figure 9. Inactivation of SHIP relieves defects of BCR-induced cal-
cium, JNK1, and Akt responses in Vav3-deficient cells. Vav3-, SHIP-,
and Vav3/SHIP double-deficient DT40 cells were stimulated with M4 (4
 g/ml) and then subjected to following analyses. (A) Calcium mobiliza-
tion, as described in the legend to Fig. 3 A. (B) Activation of JNK1, as
described in the legend to Fig. 3 E. IP, immunoprecipitation. (C) Activa-
tion of Akt, as described in the legend to Fig. 4 B.
Figure 10. Overexpression of Vav2 restores BCR-induced Rac1, Akt,
calcium responses in Vav3-deficient cells. (A) Expression levels of Vav2.
Whole-cell lysates prepared from wild-type (wt), Vav3-deficient, and
Vav3-deficient overexpressing Vav2 DT40 cells were analyzed by West-
ern blotting with anti-Vav2 Abs. Cells were stimulated with M4 (4  g/
ml) and then subjected to following analyses. (B) Rac1 activation, as de-
scribed in the legend to Fig. 5 B. AP, affinity precipitation. (C) Akt acti-
vation, as described in the legend to Fig. 4 B. IP, immunoprecipitation.
(D) Calcium mobilization, as described in the legend to Fig. 3 A.197 Inabe et al.
thereby making a positive feed-forward regulatory loop; (b)
PI3K-mediated Vav3 activation mechanism does not oper-
ate significantly in the context of BCR signaling. Our data
support the second possibility. Deletion of PI3K p110  af-
fects neither Vav3 tyrosine phosphorylation nor Rac1 acti-
vation. In addition, as reported previously in Fc RI signal-
ing (47), these readouts could not be affected in DT40 B
cells, even when PIP3 generation was almost completely in-
hibited by wortmannin (Fig. 8, A and B). However, given
the evidence that PIP3 cannot activate nonphosphorylated
Vav1 (7), one interpretation for our results is that a role of
PIP3 is the fine modulation of the enzyme activity of Vav3
only after being phosphorylated, rather than acts as a critical
Vav3 regulator. This fine modulation by PIP3 might have
escaped detection in our experimental conditions.
Activation of PI3K upon BCR engagement is thought
to involve recruiting PI3K to GEMs as well as increasing
the specific activity of the enzyme. BCR-induced translo-
cation of PI3K to GEMs occurs normally in Vav3-deficient
DT40 cells (Fig. 6), which suggests that other molecules
play a major role in PI3K recruitment to GEMs, whereas
Vav3 participates in upregulation of the PI3K enzymatic
activity. Like PI3K, Vav3 is also targeted to GEMs after re-
ceptor cross-linking (data not shown), thereby being able
to gain access to its substrate Rac1, as Rac1 is known to be
concentrated in GEMs (48). Subsequently, PI3K is acti-
vated by GTP-bound Rac1. In regard to recruitment of
PI3K to GEMs, docking proteins such as CD19, Gab, and
BCAP could participate in this process, directly or indi-
rectly, because these proteins, after being tyrosine phos-
phorylated, associate with the SH2 domains of the PI3K
p85 subunit (27, 49–52). Colocalization of Vav3 and PI3K
in GEMs appears to be necessary, but their mere colocal-
ization in GEMs might not be sufficient for PIP3 genera-
tion. For instance, when CD19 is tyrosine phosphorylated
upon BCR ligation alone or coligation of BCR and CD19,
the phosphorylated CD19 provides binding sites for both
Vav1 and PI3K (51, 53). Assuming that Vav3, like Vav1, is
recruited to the phosphorylated CD19, CD19 can bring
Vav3 and PI3K into the close proximity with each other,
which in turn, could facilitate the efficient coupling be-
tween Vav3 and PI3K in B cells. Thus, an organized multi-
protein complex including Vav3 and PI3K in GEMs may
be required for efficient PIP3 generation.
The reduced PLC- 2 activation in Vav3-deficient DT40
B cells after BCR engagement could be accounted for by
the decreased PI3K activation. In support of this explana-
tion, the PLC- 2/calcium defects in Vav3-deficient B cells
are relieved by deletion of a PIP3 hydrolyzing enzyme,
SHIP. In fact, consistent with a previous report using
SHIP /  primary B cells (54), PIP3 levels upon BCR acti-
vation are increased in SHIP-deficient DT40 B cells (Fig. 4
A). PIP3 is thought to function as a positive regulator of
PLC- 2 via two distinct mechanisms. One mechanism is
that PIP3 is involved in PLC- 2 activation through its
binding to the Btk PH domain and its subsequent activa-
tion (31, 37), as Btk is essential for PLC- 2 activation upon
BCR engagement. In this regard, we observed reduced
BCR-mediated tyrosine phosphorylation of Btk in Vav3-
deficient DT40 cells, compared with wild-type cells (Fig. 4
D). The second mechanism is that the PLC- 2 PH domain
binds to PIP3, which in turn contributes to PLC- 2 activa-
tion by its targeting to GEMs and/or by its conformational
changes (55–57). Although it is clear that PIP3-mediated
PLC- 2 activation contributes to calcium mobilization,
this mechanism may not entirely account for the effect of
Vav3 on calcium mobilization. For example, activated
Rac1 could directly modulate a calcium influx channel on
the plasma membrane (58), in addition to activating PI3K.
Given our previous evidence that calcium mobilization,
in addition to Rac1 activation, is required for coupling
BCR to JNK1 (20, 22), the reduced activation of JNK1 in
Vav3-deficient cells could be explained, at least in part, by
the insufficient calcium mobilization. Indeed, Vav3/SHIP
double-deficient DT40 B cells exhibit augmentation in
both calcium mobilization and JNK1 activation (Fig. 9, A
and B). Thus, it is reasonable to anticipate that Rac1 regu-
lates MAP3K as well as PLC- 2, both of which contribute
to the optimal JNK1 response in the BCR signaling con-
text.
Although this study has not addressed the functional dif-
ferences among Vav isoforms, our results demonstrate that
Vav2, when overexpressed, can compensate for Vav3-reg-
ulated Rac1 activation and calcium flux in B cells. Thus,
given the previous evidence that both Vav1 and Vav2 are
able to augment calcium flux and NF-AT activation in B
cell lines (18), we suggest that all three Vav isoforms possess
overlapping functions in BCR signaling. Consistent with
this, mice deficient in Vav1 or Vav2 show a modest defect
in calcium mobilization in response to BCR cross-linking,
whereas this defect is exaggerated in mice lacking both
Vav1 and Vav2 (16, 17). Hence, the mechanism we have
described for Vav3 in chicken B cells is likely to be applica-
ble to other Vav isoforms in the B cell context. Indeed, in
agreement with our conclusion, recent works from other
groups have shown that Vav1 could also regulate antigen
receptor-induced PI3K activation in murine mast cells (15)
and thymocytes (unpublished data).
Our implications, however, do not invalidate the previ-
ous contention that each Vav isoform has an unique func-
tion in other cell types. For instance, T cell studies demon-
strate that Vav1 and Vav3 are not simply interchangeable in
that overexpression of Vav1, but not Vav3, potentiates
TCR-mediated NF-AT activation (59). Considering that
Vav family proteins must associate with adaptor molecules
for exerting their functions, the inability of Vav3 to induce
calcium signaling in T cells may be due to its insufficient
interaction with adaptor molecules such as SLP-76 (60). In
contrast, BLNK and CD19 in B cells may interact with
Vav3 and Vav1 with the same efficiency (40, 51, 53, 61,
62). Differences in the substrate specificity of the Rho fam-
ily GTPases between Vav1 and Vav3 could be another pos-
sibility. High preference of Vav1 toward Rac1 might be re-
quired for T cells to activate calcium signaling. Thus, each
Vav isoform, like Vav1, has GEF-dependent and -indepen-
dent functions (23), both of which coordinately contribute198 A Role of Vav3 in BCR Signaling
to signal transduction pathways, depending upon differen-
tial cellular contexts.
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